0.00Open0.00Pre Close0 Volume0 Open Interest2.50Strike Price0.00Turnover0.00%IV82.60%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier34DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma--Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Cidara Therapeutics Stock Discussion
Cidara Therapeutics Announces First Subjects Dosed in Phase 2b NAVIGATE Trial Evaluating CD388 for the Prevention of Seasonal Influenzau
SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced the first sub...
Dow Jones· 1 min ago
NEWS
Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024
Cidara Therapeutics announced data presentations at ESCMID 2024 on CD388, highlighting Phase 1 and Phase 2a clinical data. The Phase 2a study showed CD388 was well-tolerated with significant antiviral effects in healthy volunteers challenged with influenza. The Phase 1 study demonstrated an extended half-life of 6-8 weeks, indicating potential f...
Larger Image: tradingview.com...
$Cidara Therapeutics (CDTX.US)$
Hopefully it'll continue to run tomorrow?
WSJ· 4 mins ago
Cidara Therapeutics said it would sell its candidiasis treatment rezafungin to its partner and buy back the license to its potential influenza-prevention treatment.
The San Diego-based biotechnology company said Wednesday that it was divesting the treatment, sold under the brand name Rezzayo, t...
No comment yet